Skip to main content
# Title Department Research Year
41 MCT4 knockdown by tumor microenvironment-responsive nanoparticles remodels the cytokine profile and eradicates aggressive breast cancer cells Department of Industrial Pharmacy 2024
42 Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists. Department of Pharmaceutical Organic Chemistry 2024
43 Regiodivergent biosynthesis of bridged bicyclononanes Department of Pharmacognosy 2024
44 Development of Oral Formulation of Lepidium Seeds Significantly Decreases the High Blood Glucose Levels in Diabetic Rats; In Vitro Formulation and In Vivo Antidiabetic Performance. Department of Industrial Pharmacy 2024
45 Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors. Department of Pharmaceutical Organic Chemistry 2024
46 Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level Department of Pharmaceutical Analytical Chemistry 2024
47 Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition Department of Pharmaceutical Organic Chemistry 2024
48 Zirconium-based hydrophobic-MOFs as innovative electrode modifiers for flibanserin determination: Exploring the electrooxidation mechanism using a comprehensive spectroelectrochemical study Department of Pharmaceutical Analytical Chemistry 2024
49 Synthesis, enzyme inhibition, and docking studies of new Schiff bases of disalicylic acid methylene-based derivatives as dual-target antibacterial agents Department of Pharmaceutical Organic Chemistry 2024
50 Pharmaceutical interventions for drug-related problems in the neonatal intensive care unit incidence, types, and acceptability Department of Clinical Pharmacy 2024